How do you pay?

How to pay the least

Ask for the cash price

Vykoura

We didn’t find one.

  1. Ask your pharmacy for Vykoura’s cash price, and one or two other pharmacies too.
  2. Vykoura’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameVykoura
Authorized genericleucovorin
Regular genericleucovorin
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Vykoura?
The original
–
–

Brand nameThe maker’s card

AVYXASSIST Copay Program

Savings card from AVYXA Pharma

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a dose

The card takes up to $25,000 a year off your co-pay.

Sign up on avyxaproducts.com 

Or call 1-866-939-8927.

In the maker’s words

“the patient out-of-pocket cost for their AVYXA product could be as low as $0…”

From the maker’s offer on avyxaproducts.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Vykoura itself, from the same company, sold without the brand name, and usually for less. For now Vykoura is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

VYKOURA is a folate analog indicated for:

  • Rescue after high-dose methotrexate therapy in adult and pediatric patients.
  • Reducing the toxicity of
    • methotrexate in adult and pediatric patients with impaired methotrexate elimination or
    • folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients.
  • Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible.
  • Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil.

Limitations of Use:

VYKOURA is not indicated for the treatment of pernicious anemia and megaloblastic anemia secondary to lack of vitamin B12, because of the risk of progression of neurologic manifestations despite hematologic remission.

Source: the FDA label for Vykoura (Avyxa Pharma, LLC), March 12, 2026. Full label on DailyMed 

Good to know